MATTIAS LUUKKONEN
Pilots at Bernardo Ctr Dr, San Diego, CA
License number
California A5112322
Issued Date
Jun 2016
Expiration Date
Jun 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
17179 Bernardo Center Dr, San Diego, CA 92128
Personal information
See more information about MATTIAS LUUKKONEN at radaris.comName
Address
Phone
7507 Garden Ct, San Diego, CA 92127
Rancho Bernardo, CA
17179 Bernardo Center Dr, San Diego, CA 92128
5225 Fiore Ter #311, San Diego, CA 92122
7507 Garden Ct, San Diego, CA 92127
Professional information
Gene Expression Profile For Kshv Infection And Methods For Treating Same
US Patent:
2005010, May 12, 2005
Filed:
Dec 23, 2004
Appl. No.:
11/019987
Inventors:
Mattias Luukkonen - San Diego CA, US
Ashlee Moses - Portland OR, US
Klaus Frueh - Portland OR, US
Jay Nelson - Tualatin OR, US
Yolanda Bell - Carlsbad CA, US
Michael Heinrich - Lake Oswego OR, US
Kenneth Simmen - Tervuren, BE
Ashlee Moses - Portland OR, US
Klaus Frueh - Portland OR, US
Jay Nelson - Tualatin OR, US
Yolanda Bell - Carlsbad CA, US
Michael Heinrich - Lake Oswego OR, US
Kenneth Simmen - Tervuren, BE
International Classification:
C12Q001/70, C12Q001/68, C12M001/34, A61K038/16
US Classification:
435005000, 435006000, 435287200, 514002000
Abstract:
The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.
Gene Expression Profile For Kshv Infection And Methods For Treating Same
US Patent:
2003019, Oct 9, 2003
Filed:
Aug 1, 2001
Appl. No.:
09/921512
Inventors:
Mattias Luukkonen - San Diego CA, US
Ashlee Moses - Portland OR, US
Klaus Frueh - Portland OR, US
Jay Nelson - Tualatin OR, US
Yolanda Bell - Carlsbad CA, US
Michael Heinrich - Lake Oswego OR, US
Kenneth Simmen - San Diego CA, US
Ashlee Moses - Portland OR, US
Klaus Frueh - Portland OR, US
Jay Nelson - Tualatin OR, US
Yolanda Bell - Carlsbad CA, US
Michael Heinrich - Lake Oswego OR, US
Kenneth Simmen - San Diego CA, US
International Classification:
A61K031/00, G06F017/60, C12Q001/70, C12Q001/68, G06F019/00, G01N033/48, G01N033/50
US Classification:
514/001000, 435/006000, 435/005000, 702/020000, 705/002000
Abstract:
The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.